Sanofi's Nuvaxovid COVID-19 Vaccine Demonstrates Superior Tolerability Profile Compared to mRNA Vaccine in Head-to-Head Study
核心洞察
Sanofi's protein-based Nuvaxovid COVID-19 (搜索) vaccine showed significantly better tolerability than mNEXSPIKE (搜索) mRNA vaccine in the COMPARE study, with fewer moderate-to-severe systemic and local symptoms.
The study found 61.3% of mNEXSPIKE (搜索) recipients experienced moderate-to-severe systemic symptoms versus 43.1% of Nuvaxovid recipients, representing an 18% risk difference.
Nuvaxovid recipients reported less disruption to daily activities including work, school, and recreational activities over seven days following vaccination.
Sanofi's protein-based COVID-19 (搜索) vaccine Nuvaxovid demonstrated significantly better tolerability compared to the mRNA vaccine mNEXSPIKE (搜索) in a head-to-head clinical study, potentially addressing a key barrier to COVID-19 vaccination uptake. The findings from the COMPARE study showed meaningful differences in both clinical measures and patient-reported outcomes that could influence vaccination behavior and routine immunization strategies.
Clinical Tolerability Results
The COMPARE study revealed substantial differences in reactogenicity between the two vaccine platforms. Among participants receiving mNEXSPIKE (搜索), 61.3% experienced moderate-to-severe (Grade 2 or 3) systemic symptoms compared to 43.1% of Nuvaxovid recipients, representing a statistically significant 18% risk difference (95% CI: 12%-24%; p<0.001).
Local reaction patterns followed a similar trend, with 58.7% of mNEXSPIKE (搜索) recipients experiencing moderate-to-severe local symptoms versus 38.7% of Nuvaxovid recipients, yielding a 20% risk difference (95% CI: 14%-26%; p<0.001).
"Across every measure we evaluated, we observed that the recombinant protein-based vaccine consistently exhibited lower reactogenicity and less disruption to patient activities than the comparator mRNA vaccine," said Dr. Marcel E. Curlin, Principal Investigator of the COMPARE study and Professor of Medicine at Oregon Health & Science University.
Patient-Reported Outcomes and Real-World Impact
Beyond clinical measures, the study captured patient-reported outcomes that demonstrate real-world relevance of the tolerability differences. Nuvaxovid recipients reported less disruption to daily activities, including work, school, recreational activities, and caretaking responsibilities, over the seven days following vaccination.
The study revealed behavioral insights into vaccination decision-making, with more than half of all participants reporting they scheduled their vaccination on a specific day of the week in anticipation of potential side effects. This finding highlights how tolerability concerns actively shape vaccination behavior and planning.
"Individuals cite side effects as a reason they avoid COVID-19 (搜索) vaccination. These differences could have a significant impact on improving vaccination uptake," Dr. Curlin noted.
Implications for Routine Vaccination Strategies
The tolerability profile differences may have broader implications for sustainable COVID-19 (搜索) vaccination programs. Thomas Triomphe, Executive Vice President, Vaccines at Sanofi, emphasized the connection between patient experience and long-term vaccination compliance.
"The patient experience with vaccination is essential, because it determines not only whether people get vaccinated, but also whether they come back year after year for routine protection," Triomphe said. "These results show that Nuvaxovid can play a meaningful role in making routine COVID-19 (搜索) vaccination a reality for more people."
Disease Burden and Vulnerable Populations
COVID-19 (搜索) continues to pose significant health risks beyond immediate respiratory illness. The disease increases long-term cardiovascular complications risk, including heart attacks and strokes, while older adults hospitalized for COVID-19 face substantially higher mortality risk than those hospitalized for influenza.
In the United States, an estimated 74% of adults have at least one risk factor for severe COVID-19 (搜索) illness, including cardiovascular disease (搜索), chronic lung disease (搜索), diabetes (搜索), and obesity (搜索). This statistic underscores the scale of the vulnerable population that could benefit from effective and well-tolerated COVID-19 vaccination options.
Vaccine Technology and Market Expansion
Nuvaxovid (NVX-CoV2705) represents a protein-based, adjuvanted vaccine developed using recombinant technology, an established platform with a long track record across multiple vaccine types. The vaccine has demonstrated high efficacy against COVID-19 (搜索) as a primary vaccination in two pivotal phase 3 studies.
Originally licensed by Novavax, Sanofi now holds market authorization for Nuvaxovid in the United States, European Union, and United Kingdom. Following its commercial launch in the US, Taiwan, and Morocco in 2025, Sanofi plans to expand Nuvaxovid's availability to additional markets including the United Kingdom, Germany, and Canada from 2026 onwards.
The availability of multiple vaccine options with different tolerability profiles may prove increasingly important for sustainable public health strategies as COVID-19 (搜索) transitions from pandemic to endemic status, particularly for addressing vaccine hesitancy and ensuring consistent vaccination coverage.